亚洲知识产权资讯网为知识产权业界提供一个一站式网上交易平台,协助业界发掘知识产权贸易商机,并与环球知识产权业界建立联系。无论你是知识产权拥有者正在出售您的知识产权,或是制造商需要购买技术以提高操作效能,又或是知识产权配套服务供应商,你将会从本网站发掘到有用的知识产权贸易资讯。

Cloned tumor specific MHC-unrestricted T Cell Receptor for gene therapy/immunotherapy of over 85% of human tumors

详细技术说明
None
*Abstract
MUC1 glycoprotein is overexpressed on the surface of a variety of epithelial tumors and has been under investigation as a target for immunotherapy. Transduction of bone marrow cells with tumor-specific TCR represents a potentially efficacious gene therapy/immunotherapy approach. MUC1-specific MHC-unrestricted TCR will make this treatment applicable to all cancer patients with MUC1 tumors, regardless of their HLA type.This invention pertains to the treatment or prevention of cancer in humans involving transfer of (a) an isolated population of cells, or (b) cells transduced with a nucleic acid encoding a receptor, into a human in need of treatment or prophylaxis for cancer. The present invention also pertains to a method of activating a signaling pathway. The invention provides a method of activating a signaling pathway in a cell. The method comprises transducing the cell with at least one nucleic acid that encodes a receptor so that the receptor is expressed and displayed on the surface of the cell. The encoded receptor is capable of binding to a MUCl antigen without requiring the MUCl antigen to be presented in the context of a major histocompatibility complex (MHC). The receptor either interacts with a signaling molecule, or comprises a signaling domain, such that when the receptor is contacted with a cell having the MUCl tumor antigen on its surface, the signaling pathway is activated.
*Principal Investigation

Name: Nehad Alajez

Department: Med-Immunology


Name: Mark Alter

Department: Department of Child and Adolescent Psychiatry


Name: Olivera Finn, Professor

Department: Med-Immunology


Name: Jan Schmielau

Department:

国家/地区
美国

欲了解更多信息,请点击 这里
移动设备